2 results
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes
The primary objective is to confirm that treatment with oral semaglutide does not result in an unacceptable increase in cardiovascular risk compared to placebo (rule out 80% excess risk) in subjects with T2D at high risk of cardiovascular events.The…
Approved WMOCompleted
The purpose of this study is to investigate how quickly and to what extent branaplam is absorbed and eliminated from the body (this is called pharmacokinetics). Branaplam will be labelled with Carbon-14 (14C) and is thus radioactive. In this way…